Printer Friendly

Global Leukemia Therapeutics Market to Reach USD 2.6bn by 2025, Research and Markets Forecasts.

M2 PHARMA-July 20, 2017-Global Leukemia Therapeutics Market to Reach USD 2.6bn by 2025, Research and Markets Forecasts


- The global leukemia therapeutics market is poised to grow at a CAGR of around 17.5% over the next decade to reach approximately USD 2.6bn by 2025, according to a report from Dublin-based Research and Markets.

Some of the prominent trends that the market is witnessing include growing prevalence of chronic diseases, increasing research and development in leukemia therapeutics, and recent technological developments in therapies.

Based on leukemia type the market is categorized into chronic leukemia, acute leukemia, chronic myeloid leukemia, acute myeloid leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, chronic lymphatic leukemia, and acute lymphatic leukemia.

Furthermore, acute lymphatic leukemia sub segmented into acute biphenotypic leukemia, burkitt leukemia, precursor B acute lymphatic leukemia, and precursor T acute lymphatic leukemia. By diagnosis the market is segmented by biopsy, CT scan, and MRI.

Depending on the treatment the market is classified into chemotherapy, bone marrow transplant, immunotherapy, stem cell therapy, radiation therapy, targeted therapy, and surgery.

On basis of Drugs the market is segmented by gleevec, ga101, dacogen, bosutinib, graspa, revlimid, omapro, marqibo, vasaroxine, tosedosat, sapacitabine, vidaza, and other drugs. By route of administration the market is segmented by intramuscular route, intrathecal route, subcutaneous route, intravenous route, and oral route.

Key players in this market includes Ambit Biosciences Corp., AriadPharmaceuticals, Inc., Biogen Idec, Inc., Bristol Myers Squibb Co, Celgene Corp., Cephalon Inc, Clavis Pharma Asa, Eisai Co. Ltd., Erytech Pharma, Genzyme Corp, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Roche Holding AG and Sanofi.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 20, 2017
Previous Article:Dicerna Expands Lead GalXCDevelopment Program to Encompass All Forms of Primary Hyperoxaluria and Reveals New Therapeutic Target for DCR-PHXC.
Next Article:Kala Pharmaceuticals Announces Prices USD 90m Initial Public Offering.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters